Sort by
Refine Your Search
-
transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it
-
, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational
-
with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance
-
acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other
-
- Alnylam, GSK ) Please ask your letter writers to complete and submit the Letter of Recommendation Form along with their recommendation. Click here to access the form and share it with your letter writers
-
your teaching philosophy The College of the Holy Cross uses Interfolio to collect all faculty job applications electronically. Please submit all application materials to https://apply.interfolio.com
-
Chiesi Global Rare Diseases - Medical Affairs Postdoctoral Research Fellow | Northeastern University
, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. No matter where your path starts at Chiesi, it
-
serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance
-
support the development of Alnylam's investigational RNAi therapeutics. Early Assets Medical Affairs partners with experts across the organization to guide each unique investigational program as it enters
-
Regulatory Fellowship is unique in that it offers the opportunity for a blended experience during the first year, encompassing both Strategy and Advertising, Promotion & Labeling. In the second year